home / stock / tbph / tbph quote
Last: | $8.51 |
---|---|
Change Percent: | 0.0% |
Open: | $8.25 |
Close: | $8.51 |
High: | $8.51 |
Low: | $8.185 |
Volume: | 230,328 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$8.51 | $8.25 | $8.51 | $8.51 | $8.185 | 230,328 | 07-04-2024 |
$8.51 | $8.25 | $8.51 | $8.51 | $8.185 | 230,328 | 07-03-2024 |
$8.32 | $8.55 | $8.32 | $8.55 | $8.32 | 168,330 | 07-02-2024 |
$8.52 | $8.46 | $8.52 | $8.64 | $8.39 | 254,801 | 07-01-2024 |
$8.48 | $8.4 | $8.48 | $8.5 | $8.31 | 1,605,706 | 06-28-2024 |
$8.33 | $8.44 | $8.33 | $8.45 | $8.28 | 242,173 | 06-27-2024 |
$8.41 | $8.39 | $8.41 | $8.55 | $8.38 | 211,331 | 06-26-2024 |
$8.4 | $8.77 | $8.4 | $8.8 | $8.39 | 369,382 | 06-25-2024 |
$8.77 | $8.74 | $8.77 | $8.95 | $8.702 | 362,766 | 06-24-2024 |
$8.75 | $8.78 | $8.75 | $8.88 | $8.71 | 615,783 | 06-21-2024 |
$8.66 | $8.47 | $8.66 | $8.73 | $8.3701 | 415,223 | 06-20-2024 |
$8.48 | $8.41 | $8.48 | $8.59 | $8.31 | 391,137 | 06-19-2024 |
$8.48 | $8.41 | $8.48 | $8.59 | $8.31 | 391,137 | 06-18-2024 |
$8.43 | $8.42 | $8.43 | $8.55 | $8.39 | 164,009 | 06-17-2024 |
$8.48 | $8.54 | $8.48 | $8.75 | $8.37 | 301,747 | 06-14-2024 |
$8.58 | $8.63 | $8.58 | $8.72 | $8.57 | 268,672 | 06-13-2024 |
$8.64 | $9.01 | $8.64 | $9.01 | $8.6 | 228,453 | 06-12-2024 |
$8.82 | $8.64 | $8.82 | $8.83 | $8.57 | 211,635 | 06-11-2024 |
$8.7 | $8.72 | $8.7 | $8.72 | $8.59 | 217,653 | 06-10-2024 |
$8.77 | $8.78 | $8.77 | $8.87 | $8.74 | 158,697 | 06-07-2024 |
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma Inc. Website:
2024-06-15 00:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire Q1 2024 YUPELRI ® (revefenacin) net sales of $55.2 million , recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboratio...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...